Consultant-Needed-Insert
X

Find Clinical Drug Pipeline Developments & Deals for 6-Hydroxymethylacylfulvene

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 6-Hydroxymethylacylfulvene

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $29.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering April 16, 2020

            Details:

            Funds is directed towards Lantern Pharma's most advanced candidate is LP-100, a potential treatment for prostate cancer that is in a Phase 2 trial with out-licensing partner Oncology Venture.